Public procurement notice: Contract Award Notice
Published: 2023-11-15
Buyer: KENTRO MELETON ASFALEIAS (KEMEA)
Country: GR
Contract type: Services
Procedure: Competitive dialogue
CPV classification: 38544000 | 72000000
Estimated value: 1400000 EUR
Award criteria: The most economic tender

Technical requirements: Υπηρεσίες τεχνολογίας των πληροφοριών: παροχή συμβουλών, ανάπτυξη λογισμικού, Διαδίκτυο και υποστήριξη
This contract notice provides information about a  public procurement of innovative solutions (PPI) carried out by the project ‘Innovation procurement for Drug Detection in correctional institutions and prisons’ — DrugDetect. This project receives co-funding by the COSME programme of the European Union under grant agreement No 101036225.
The DrugDetect project aims to procure an innovative solution for the automatic detection of a large range of drugs in correctional institutions and prisons, that is available 24/7, does not cause delays in internal processes, does not require minimal human intervention, and is GDPR compliant.
Following the identified needs and the market analysis, the DrugDetect Buyer’s Group decided to pursue 3 Lots during the present procurement procedure:
The solution proposed by the Tenderer must comprise one or more innovative components or one or more architectural innovations. The Drug Detect procurement does not include the procurement of research and development (R&D).
In particular, the proposed solution must comprise new or significantly improved components or architecture that have already been (partially) demonstrated on a small scale and may be nearly or already available in small quantities on the market, but which have not been widely adopted yet. Typically, owing to the residual risk or market uncertainty, these innovative components or architecture have not been produced at a large enough scale. This also includes existing solutions that are to be utilised in a new and innovative way.
Whether a component or architectural feature is innovative will be assessed by the Drug Detect consortium according to the following three cumulative minimum requirements:
1. The innovative component or architectural innovation must be related to innovation aspects indicated as important for the given lot.
2. The difference in time between first deployment of the device/solution, which is equipped with such a component or is based on such architectural innovations, and the date, when the given Tender was due for submission, must not exceed 24 months.
3. Finally, the component or architectural innovation in question must not have been used for more than 50 clients.
These cumulative minimum requirements will be assessed for each bid submitted. Final Tenders that do not conform to this minimal requirement will be excluded.
This project receives co-funding by the COSME programme of the European Union under grant agreement No 101036225.
The contracting authority involved in the DrugDetect  project is not legally bound in any way by the outcome of the market consultation. The open market consultation will provide an overview on the procurement objectives, the PPI process and the main clauses of the contract. It is also not part of any pre-qualification or selection process. No advantage or disadvantage will be given to any supplier / group of suppliers to the detriment of others during the market consultation and the sub-sequent competitive procedure for the award of contracts procurement.
All communication will be carried out in English via the email  drugdetect_procurement@kemea-research.gr
All information provided during the open market consultation and other background information will be published online in English.


Winner: 908 Devices Inc
Award value: 1400000
Number of bids: 3